CA
LKFT

Claro Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Claro Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-382
Closed -$43K – 469
2018
Q4 		$43K Buy
+382
New +$38.7K 0.03% 360

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Claro Advisors's LKFT Position: Q1 2019 in Review

Claro Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2019, closing a stake of 382 shares — an estimated $43K sold.

Claro Advisors first reported a position in LKFT in Q4 2018 and held it in 1 quarter. The position peaked at $43K in Q4 2018. 92 funds tracked by Wall St. Rank hold LKFT as of Q1 2019.

  • Claro Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2019 after selling out during the quarter.
  • Claro Advisors sold 382 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2019, an estimated $43K.
  • Claro Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and held it in 1 quarter.
  • Claro Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $43K in Q4 2018.
  • 92 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.